|
Dr. William Claypool has been chief executive officer and chairman of Phoenix Data Systems since 2001. Dr. Claypool has managed more than 34 regulatory filings and supported nearly two dozen pharmaceutical product launches. He left SmithKline Beecham at the time of the merger with GlaxoWelcome in January of 2001. During his tenure at SmithKline Beecham, Dr. Claypool established electronic data capture as the preferred platform for data management at the company. Dr. Claypool joined SmithKline Beecham Pharmaceuticals in 1991 as a vice president, initially as head of the Cardiopulmonary Therapeutic Unit, then the Inflammation and Tissue Repair Therapeutic Unit. In 1995, he became the vice president and director of North America clinical research and development and medical affairs, and in 1998, senior vice president for development operations and research and development portfolio management. Later in 1998, he was appointed senior vice president and director of worldwide clinical development and medical affairs, responsible for global clinical drug development, including clinical statistics and data management. Dr. Claypool is a graduate of the University of Notre Dame and the University of Connecticut School of Medicine. He performed his medical residency and pulmonary medicine fellowship at the Hospital of the University of Pennsylvania. After serving on several medical school faculties, he began a career in clinical research for the pharmaceutical industry. | 